Novo, MIT develop oral biologic delivery device

A team including Massachusetts Institute of Technology and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) scientists have developed an ingestible pill-sized device that can deliver drugs, including insulin, directly to the gastric mucosa.

The device -- called

Read the full 359 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE